NZ591008A - Purin derivatives for use in the treatment of fab-related diseases - Google Patents
Purin derivatives for use in the treatment of fab-related diseasesInfo
- Publication number
- NZ591008A NZ591008A NZ591008A NZ59100809A NZ591008A NZ 591008 A NZ591008 A NZ 591008A NZ 591008 A NZ591008 A NZ 591008A NZ 59100809 A NZ59100809 A NZ 59100809A NZ 591008 A NZ591008 A NZ 591008A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- fab
- treatment
- compounds
- related diseases
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ604091A NZ604091A (en) | 2008-08-15 | 2009-08-13 | Purin derivatives for use in the treatment of fab-related diseases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08060740 | 2008-08-15 | ||
EP09150252 | 2009-01-08 | ||
EP09160682 | 2009-05-19 | ||
PCT/EP2009/060521 WO2010018217A2 (en) | 2008-08-15 | 2009-08-13 | Organic compounds for wound healing |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ591008A true NZ591008A (en) | 2013-06-28 |
Family
ID=48670214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ591008A NZ591008A (en) | 2008-08-15 | 2009-08-13 | Purin derivatives for use in the treatment of fab-related diseases |
Country Status (2)
Country | Link |
---|---|
CL (1) | CL2011000328A1 (en) |
NZ (1) | NZ591008A (en) |
-
2009
- 2009-08-13 NZ NZ591008A patent/NZ591008A/en unknown
-
2011
- 2011-02-15 CL CL2011000328A patent/CL2011000328A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2011000328A1 (en) | 2011-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ593754A (en) | Dpp-iv inhibitors for treatment of diabetes in paediatric patients | |
Zank et al. | Idiopathic pulmonary fibrosis: aging, mitochondrial dysfunction, and cellular bioenergetics | |
NZ605207A (en) | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug | |
NZ590787A (en) | DPP-4 inhibitors for treating diabetes in patients showing contraindication against metformin therapy | |
WO2010018217A3 (en) | Purin derivatives for use in the treatment of fab-related diseases | |
NZ625577A (en) | Therapeutic uses of pharmaceutical compositions | |
WO2009044392A3 (en) | Novel sirna structures | |
US9526728B2 (en) | Medical use of a DPP-4 inhibitor | |
RS53272B (en) | Uses of dpp-iv inhibitors | |
NZ603319A (en) | Diabetes therapy | |
WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
NZ599298A (en) | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin | |
WO2008124085A3 (en) | Methods of using combinations of mek and jak-2 inhibitors | |
CA2914791A1 (en) | Dpp-4 inhibitors for treating diabetes and its complications | |
WO2009071480A3 (en) | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | |
JP2016518438A5 (en) | ||
NO20083004L (en) | Use of benzofused heterocyclic sulfamide derivatives for the treatment of drug addiction | |
JP2012515176A (en) | SGC stimulators or sGC activators in combination with PDE5 inhibitors for the treatment of erectile dysfunction | |
WO2010098600A3 (en) | Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same | |
AR079057A1 (en) | URINARY TRIAOSILCERAMIDE (GB3) AS A CARDIAC DISEASE MARKER | |
WO2007149283A3 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
WO2008026156A3 (en) | Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor | |
BR112014012054A2 (en) | deferiprone treatment methods | |
MX345032B (en) | Selective ep4 receptor agonistic substance for treatment of cancer. | |
WO2007113243A3 (en) | Use of pde 5 inhibitors for the treatment of overactive bladder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 AUG 2016 BY SPRUSON + FERGUSON Effective date: 20131121 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2017 BY DENNEMEYER + CO. Effective date: 20160722 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2018 BY DENNEMEYER + CO Effective date: 20170726 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2019 BY DENNEMEYER + CO Effective date: 20180803 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2020 BY DENNEMEYER + CO. Effective date: 20190719 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2021 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20200804 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2022 BY DENNEMEYER + CO. Effective date: 20210802 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2023 BY DENNEMEYER + CO. SARL. Effective date: 20220801 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 AUG 2024 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20230731 |